A Nationwide Post-marketing Study on the Safety of Abatacept Treatment in Sweden Using the ARTIS Register
N/A
N/A
N/A
N/A
N/A
Open (Enrolling)
Both
Rheumatoid Arthritis
Both
Rheumatoid Arthritis
Trial Information
A Nationwide Post-marketing Study on the Safety of Abatacept Treatment in Sweden Using the ARTIS Register
Inclusion Criteria:
- Resident of Sweden
Exclusion Criteria:
- None
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Hospitalized infection
Outcome Time Frame:
Every 6 months throughout the study
Safety Issue:
Yes
Principal Investigator
Bristol-Myers Squibb
Investigator Role:
Study Director
Investigator Affiliation:
Bristol-Myers Squibb
Authority:
European Union: European Medicines Agency
Study ID:
IM101-125
NCT ID:
NCT01094795
Start Date:
July 2008
Completion Date:
October 2017
Related Keywords:
- Rheumatoid Arthritis
- Arthritis
- Arthritis, Rheumatoid
Name | Location |
|---|
